Acq Pharma

ACQ Pharma is a clinical-stage biotechnology company focused on developing innovative small molecule drugs for the treatment of hematologic disorders. The company's lead candidate, ACQ-001, is an orally administered small molecule designed to induce the production of fetal hemoglobin (HbF). This approach aims to treat hemoglobinopathies, including Sickle Cell Disease and Beta-Thalassemia, by compensating for defective adult hemoglobin. Headquartered in Suzhou, China, the company is backed by leading venture capital firms such as Qiming Venture Partners and Lilly Asia Ventures. ACQ Pharma's mission is to provide effective and convenient therapeutic options for patients with genetic blood diseases. The company positions its oral small molecule platform as a potentially more accessible and cost-effective alternative to complex gene therapies.